Greetings and welcome to the TG Therapeutics fourth quarter and full year conference call and webcast. (Operator Instructions). As a reminder, this conference is being recorded. It's all my pleasure ...

Q4 2024 Earnings Call Transcript March 3, 2025 TG Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.15, ...

TG Therapeutics' Q4 2024 EPS of $0.15 beat the forecast of $0.08. Revenue for the quarter was $108.19 million, exceeding the $97.66 million forecast. The stock price increased by 5.47% in ...

TG cautions that these forward-looking statements ... With that, I will now turn the call back over to the - conference operator, to begin the Q&A. Hi, good morning and thank you for taking ...

Reports Q4 revenue $108.185M, consensus $100.67M. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, “2024 was a year ...

MORRISVILLE, N.Y. (AP) — MORRISVILLE, N.Y. (AP) — TG Therapeutics Inc. (TGTX) on Monday reported fourth-quarter earnings of $23.3 million. On a per-share basis, the Morrisville, New York-based ...

Q4 2024 Management View CEO Michael Weiss highlighted the strong full-year 2024 U.S. revenue of $310 million for BRIUMVI, exceeding initial guidance and reflecting the therapy's value in treating ...

MORRISVILLE, N.Y. (AP) — MORRISVILLE, N.Y. (AP) — TG Therapeutics Inc. (TGTX) on Monday reported fourth-quarter earnings of $23.3 million. On a per-share basis, the Morrisville, New York-based company ...

The company reported a Q4 EPS of $0.15, which was $0.07 higher than the analyst estimate of $0.08. Revenue for the quarter came in at $108.19 million, outpacing the consensus estimate of $97.66 ...

Shares of TG Therapeutics shares rose after it swung to a profit in the fourth quarter. The stock climbed 17% to $35.27 in midday trading on Monday. Shares have almost doubled in the past year. The ...